No Data
Longevity Biomedical to Go Public in SPAC Deal With FutureTech II Acquisition
Longevity Biomedical: Late Stage, Diversified Pipeline of Therapeutic Candidates Across Ophthalmology, Cardiovascular Disease and Soft Tissue Reconstruction and Repair >FTII
Longevity Biomedical: Combination Expected to Close in 4Q >FTII
Express News | Futuretech II Acquisition Corp: Estimated Cash Proceeds Available to Combined Co From Deal Consists of Futuretech's $26.8 Mln of Cash Held in Trust
Express News | Futuretech II Acquisition Corp - Combined Company to List on Nasdaq Under Ticker 'lbio'
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity
No Data
No Data
